New Digital PCR Assays Enable Accurate and Sensitive Detection of Critical Pathogens
|
By LabMedica International staff writers Posted on 30 Sep 2024 |
|
QIAGEN (Venlo, the Netherlands) has introduced 100 new assays for its QIAcuity digital PCR (dPCR) platform, aimed at advancing research in areas such as cancer, inherited genetic disorders, and infectious disease surveillance. These new assays are part of QIAGEN's comprehensive GeneGlobe platform, which combines pre-designed assays with a database containing over 10,000 biological entities, including genes, miRNAs, and pathways.
The newly released assays include dPCR LNA (locked nucleic acid) Mutation Assays and dPCR CNV (copy number variation) Probe Assays, specifically designed to investigate mutations and CNVs linked to cancer. This includes mutations associated with colorectal cancer, sarcomas, and thyroid cancer. Additionally, the new dPCR Microbial DNA Detection Assays target key pathogens that cause infectious diseases, tropical diseases, sexually transmitted infections, urinary tract infections, and genes related to antibiotic resistance. In 2024 alone, QIAGEN has launched over 130 new assays, adding to its portfolio of more than 2,300 validated assays.
The QIAcuity digital PCR platform uses nanoplates to partition samples into thousands of micro-reactions, detecting even the smallest traces of DNA and RNA. This platform integrates partitioning, thermocycling, and imaging into a streamlined multiplex workflow, cutting processing time from six hours to just two. It is available in one-, four-, and eight-plate configurations to accommodate different lab sizes and throughput needs. Looking ahead, QIAGEN plans to launch an in-vitro diagnostic version of QIAcuity in the fall of 2024, enabling clinical applications such as diagnosing infectious diseases and monitoring cancer progression and treatment responses using less invasive liquid biopsies.
“This important expansion of the menu for QIAcuity digital PCR underscores how QIAGEN is addressing the urgent needs of our customers for new solutions to help use this powerful technology in research and applied testing applications,” said Nitin Sood, Senior Vice President, Head of the Life Sciences Business Area at QIAGEN. “QIAcuity is proving to be a valuable tool for a broad range of applications requiring accurate and sensitive detection of genetic targets, driving the development of new multiplexed assay capabilities. Our efforts won’t stop here as we look to further expand QIAcuity into clinical and biopharma applications as well as new areas of Life Sciences research.”
Related Links:
QIAGEN
Latest Microbiology News
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
- Culture-Free Platform Rapidly Identifies Blood Stream Infections
- POC PCR Test Rapidly Detects Bacterial Meningitis Directly at Point of Sample Collection
- Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris
- Ultra-Rapid AST System Provides Critical Results for Sepsis Patients
Channels
Clinical Chemistry
view channel
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
Accurately monitoring drug levels in the blood is essential for effective treatment, particularly in the management of cardiovascular diseases. Traditional techniques for monitoring blood drug levels often... Read more
Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients.... Read more
Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. However, detecting proteins at extremely low ... Read moreMolecular Diagnostics
view channel
New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more
Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Cancer remains one of the leading causes of death globally, underscoring the critical need for more advanced, efficient, and early detection methods. Circulating tumor cells (CTCs) are cells that have... Read more
Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more
Hematology
view channel
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
WBC Count Could Predict Severity of COVID-19 Symptoms
The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment... Read more
New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions,... Read more
Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
Heparin-induced thrombocytopenia (HIT), a serious side effect of the blood thinner heparin, is difficult to diagnose because thrombocytopenia, or low platelet count, can be caused by a variety of factors... Read moreImmunology
view channel
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more
Pathology
view channel
Informatics Solution Elevates Laboratory Efficiency and Patient Care
QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read more
Technology
view channel
POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
Cardiovascular diseases continue to be the leading cause of death worldwide, accounting for over 19 million fatalities annually. Early detection of myocardial infarction (MI), commonly known as a heart... Read more
Study Explores Impact of POC Testing on Future of Diagnostics
In today’s rapidly changing world, having quick and accurate access to medical information is more crucial than ever. Point-of-Care Diagnostics (PoC-D) and Point-of-Care Testing (PoC-T) are making this... Read more
Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
Cancer biomarkers are valuable tools for early diagnosis as their concentration in body fluids, such as serum, can be measured to detect the disease at an earlier stage. Additionally, serum levels of these... Read more
Industry
view channel
CACLP 2025 Unites Global Innovators in IVD Industry
CACLP (Shanghai, China) will be holding the 22nd China International In Vitro Diagnostic Expo, the largest and most influential gathering of the IVD industry in China, 22-24 March 2025 at the Hangzhou... Read more
Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with... Read more
